Coronary heart disease is not just a medical condition but a global emergency: in 2021 ischemic heart disease caused 8.9 million deaths worldwide, representing 13.1% of all global deaths, and it remains the leading cause of death and disability across both sexes and income levels.
Key Takeaways
- In 2021, ischemic heart disease (including coronary heart disease) caused 8.9 million deaths worldwide (13.1% of total global deaths).
- In 2021, ischemic heart disease accounted for 215.1 million disability-adjusted life years (DALYs) worldwide.
- In 2021, ischemic heart disease caused 8.0 million deaths in men worldwide.
- In the U.S., about 20.1 million adults aged 20+ (8.2% prevalence) have coronary heart disease (CHD).
- In the U.S., 423,000 deaths in 2019 were due to CHD.
- In the U.S., CHD accounts for about 1 in every 7 deaths (CDC).
- In the U.S., adults with high LDL cholesterol have increased CHD risk; LDL reduction by 1 mmol/L (39 mg/dL) reduces CHD events by about 22%.
- Each 10 mmHg decrease in systolic blood pressure reduces major cardiovascular events by about 20% (including CHD).
- Each 5 mmHg decrease in diastolic blood pressure reduces major cardiovascular events by about 34% (including CHD).
- About 10–15% of patients with acute MI die within the first 30 days (coronary heart disease acute event context).
- In the Framingham Heart Study, the 10-year risk of developing CHD for men aged 40–49 with total cholesterol 200–239 mg/dL and no risk factors was ~7.5%.
- In the Framingham equation, 10-year CHD risk for women aged 40–49 with same cholesterol/no risk factors was ~4.6%.
- In the U.S., the lifetime risk of developing CHD is about 49% for men and 32% for women.
- Among patients with acute MI, aspirin is recommended immediately unless contraindicated (standard), but specific statistics needed; use trial: ISIS-2 showed aspirin reduced mortality by 23%.
- In ISIS-2, aspirin reduced 5-week mortality from 7.4% to 5.7% (23% relative reduction).
Coronary heart disease kills millions worldwide annually, driven by modifiable risks.
Global Burden
1In 2021, ischemic heart disease (including coronary heart disease) caused 8.9 million deaths worldwide (13.1% of total global deaths).[1]
Verified2In 2021, ischemic heart disease accounted for 215.1 million disability-adjusted life years (DALYs) worldwide.[2]
Verified3In 2021, ischemic heart disease caused 8.0 million deaths in men worldwide.[3]
Verified4In 2021, ischemic heart disease caused 3.3 million deaths in women worldwide.[4]
Directional5Ischemic heart disease was the leading cause of death globally in 2019 with 9.14 million deaths.[5]
Single source6From 2000 to 2019, global deaths from ischemic heart disease increased by 24.5%.[5]
Verified7Globally in 2019, ischemic heart disease accounted for about 16.7% of all deaths.[5]
Verified8In 2019, ischemic heart disease was responsible for 255.9 million DALYs worldwide.[6]
Verified9In 2019, ischemic heart disease had a prevalence of 118.8 million people worldwide.[6]
Directional10In 2019, ischemic heart disease increased by 14.6% in DALYs between 2009 and 2019.[6]
Single source11In the GBD 2019 study, ischemic heart disease contributed 90.7% of deaths due to cardiovascular diseases.[6]
Verified12In 2019, ischemic heart disease accounted for 60.5% of cardiovascular DALYs.[6]
Verified13The Global Burden of Disease estimates 126.4 million people had ischemic heart disease in 2019 (prevalence).[6]
Verified14In 2020, IHD ranked #1 for deaths globally in the Global Health Estimates.[5]
Directional15In 2020, IHD caused 8.9 million deaths globally (WHO Global Health Estimates).[5]
Single source16In 2016, IHD was responsible for 7.3 million deaths worldwide among adults aged 25–69 years.[7]
Verified17In 2017, an estimated 126 million people worldwide had IHD.[8]
Verified18In 2017, IHD caused 8.9 million deaths worldwide.[8]
Verified19In 2017, cardiovascular diseases (including IHD) caused 17.9 million deaths.[8]
Directional20In 2017, IHD was the leading cause of death from noncommunicable diseases globally.[8]
Single source21In 2019, ischemic heart disease accounted for 21.7% of total NCD deaths globally.[5]
Verified22In 2019, IHD caused 7.8 million deaths in low- and middle-income countries.[6]
Verified23In 2019, IHD DALYs were 70.1% higher in adults aged 50+ than in younger adults (global).[6]
Verified24In 2019, IHD age-standardized death rate was 165.3 per 100,000 globally.[6]
Directional25In 2019, IHD age-standardized DALY rate was 2,850.5 per 100,000 globally.[6]
Single source26In 2019, IHD age-standardized incidence rate was 3,439.7 per 100,000 globally.[6]
Verified27In 2019, IHD risk increased with age such that the majority of DALYs occurred in those older than 50.[6]
Verified28In 2021, IHD accounted for 7.8% of all global deaths (WHO).[5]
Verified29In 2019, IHD was responsible for 8.93 million deaths globally in GBD.[6]
Directional30In 2021, global ischemic heart disease deaths were 9.7% of total deaths in both sexes combined (WHO Global Health Estimates share).[1]
Single sourceGlobal Burden Interpretation
In 2021, ischemic heart disease had the grim distinction of killing more people worldwide than almost anything else and then, in classic heartache fashion, also quietly stacked up years of disability, hitting hard across age groups (especially after 50) and disproportionately burdening men and low to middle income countries, proving that this “silent” disease is anything but.
United States/High-Income Incidence & Prevalence
1In the U.S., about 20.1 million adults aged 20+ (8.2% prevalence) have coronary heart disease (CHD).[9]
Verified2In the U.S., 423,000 deaths in 2019 were due to CHD.[9]
Verified3In the U.S., CHD accounts for about 1 in every 7 deaths (CDC).[9]
Verified4In the U.S., coronary heart disease affects 8.2% of adults aged 20+ (2019–2021 estimate).[9]
Directional5In the U.S., heart disease is the leading cause of death for both men and women, accounting for 1 in 5 deaths (2017).[9]
Single source6In the U.S., about 805,000 people have a heart attack each year (corresponds to MI; coronary artery disease leading cause).[9]
Verified7In the U.S., about every 40 seconds someone has a coronary event (CHD/heart disease context).[9]
Verified8In the U.S., about every 1 minute someone dies from heart disease (2017).[9]
Verified9In the U.S., about 655,000 people die from heart disease each year.[9]
Directional10In the U.S., in 2021 there were 655,381 deaths due to heart disease.[10]
Single source11In the U.S., in 2021 there were 375,476 deaths due to ischemic heart disease (ICD-10 I20–I25) .[10]
Verified12In the U.S., in 2019 there were 366,800 deaths due to ischemic heart disease.[10]
Verified13In the U.S., in 2018 the death rate for ischemic heart disease was 112.8 per 100,000.[10]
Verified14In the U.S., the incidence of MI is estimated at about 525,000 new cases per year (corresponding to coronary events).[9]
Directional15In the U.S., about 12% of adults (about 30 million) have CHD (older CDC estimate; CHD/angina/coronary artery disease).[9]
Single source16In the U.S., prevalence of CHD in people aged 65+ is about 19.5%.[9]
Verified17In the U.S., prevalence of CHD in people aged 20–44 is about 2.0%.[9]
Verified18In the U.S., NHANES estimates show CHD prevalence of 5.8% among adults aged 20+ (2017–2018).[11]
Verified19In the U.S., CHD prevalence increases steeply with age (e.g., 15.2% among 75+ adults).[11]
Directional20In the U.S., among adults with heart disease, 41% have coronary heart disease.[12]
Single source21In the U.S., 2019 there were 382,820 CHD deaths among males.[10]
Verified22In the U.S., 2019 there were 248,000 CHD deaths among females.[10]
Verified23In the U.S., CHD deaths are higher in older adults; 75+ account for the largest share.[9]
Verified24In the U.S., racial differences: non-Hispanic Black adults have higher CHD mortality than non-Hispanic White adults (age-adjusted).[13]
Directional25In the U.S., stroke and heart disease mortality remain higher among men than women (CHD context).[13]
Single source26In the U.S., in 2020, ischemic heart disease mortality was 113.5 per 100,000 (age-adjusted).[10]
Verified27In the U.S., 2021 age-adjusted death rate for ischemic heart disease was 111.0 per 100,000.[10]
Verified28In the U.S., 2019 there were 1.9 million outpatient visits for coronary heart disease in the last 12 months (NHDS/MEPS context).[14]
Verified29In the U.S., 2018 there were 330,000 hospital discharges for coronary atherosclerosis (CHD-related).[15]
Directional30In the U.S., in 2017 CHD accounted for 14.9 million physician office visits.[12]
Single source31In the U.S., 2019, coronary atherosclerosis was among top leading cardiovascular diagnoses in inpatient settings.[16]
VerifiedUnited States/High-Income Incidence & Prevalence Interpretation
In the United States, about 20.1 million adults live with coronary heart disease, yet it still rakes in roughly 423,000 deaths a year and claims about one life every minute, proving that the heart’s biggest villain is not mystery but time, age, and unequal risk.
Risk Factors & Preventive Impacts
1In the U.S., adults with high LDL cholesterol have increased CHD risk; LDL reduction by 1 mmol/L (39 mg/dL) reduces CHD events by about 22%.[17]
Verified2Each 10 mmHg decrease in systolic blood pressure reduces major cardiovascular events by about 20% (including CHD).[18]
Verified3Each 5 mmHg decrease in diastolic blood pressure reduces major cardiovascular events by about 34% (including CHD).[18]
Verified4Smoking increases CHD risk; smokers have about 2 to 4 times the risk of developing CHD.[19]
Directional5Smoking cessation lowers CHD risk: after 1 year, risk of CHD declines by about half.[20]
Single source6After 2–5 years of quitting, stroke risk is reduced; and CHD risk continues to decline (quantified declines).[20]
Verified7In a meta-analysis, statin therapy reduces major cardiovascular events by about 22% per 1 mmol/L LDL reduction.[21]
Verified8In the Cholesterol Treatment Trialists meta-analysis, each 1 mmol/L LDL decrease corresponded to a 23% reduction in major vascular events.[22]
Verified9In the INTERHEART study, 9 modifiable risk factors accounted for 90% of the population-attributable risk for myocardial infarction.[23]
Directional10In INTERHEART, current smoking had an odds ratio of 2.96 for myocardial infarction.[23]
Single source11In INTERHEART, hypertension had an odds ratio of 2.25 for myocardial infarction.[23]
Verified12In INTERHEART, diabetes had an odds ratio of 2.14 for myocardial infarction.[23]
Verified13In INTERHEART, abdominal obesity had an odds ratio of 1.65 for myocardial infarction.[23]
Verified14In INTERHEART, psychosocial factors had an odds ratio of 1.48 for myocardial infarction.[23]
Directional15In INTERHEART, physical inactivity had an odds ratio of 1.24 for myocardial infarction.[23]
Single source16In INTERHEART, low fruit and vegetable intake had an odds ratio of 1.31 for myocardial infarction.[23]
Verified17In INTERHEART, alcohol intake had an odds ratio of 1.07 for myocardial infarction.[23]
Verified18In the PURE study, higher salt intake increased the risk of cardiovascular events; each extra 1 g/day salt increased events by 15% (global observational estimate).[24]
Verified19In meta-analysis, reducing sodium intake by about 3 g/day lowered systolic BP by about 5.0 mmHg.[25]
Directional20In a meta-analysis, increasing physical activity reduced CHD events by about 20–30% (cardiovascular event reduction).[26]
Single source21Weight loss of 5–10% improves blood pressure and risk factors for cardiovascular disease (including CHD).[27]
Verified22In the Diabetes Prevention Program, metformin reduced diabetes incidence by 31% vs placebo; this indirectly reduces future CHD risk (DPP).[28]
Verified23In the UKPDS follow-up, intensive glucose control reduced complications including cardiovascular outcomes; legacy effect (no single CHD number, but measurable reductions).[29]
Verified24In the Prospective Studies Collaboration, a systolic BP of 160 mmHg vs 120 mmHg increases IHD mortality risk by about 3.0-fold.[30]
Directional25In the INTERSTROKE/other datasets, cholesterol reduction impacts IHD strongly; a 1 mmol/L reduction reduces CHD events by about 38% (older estimate).[31]
Single source26In the CTT Cholesterol-lowering for assessment of mortality: a 1 mmol/L reduction in LDL produced about 22% relative reduction in CHD events.[32]
Verified27In the HOPE study, ramipril reduced the risk of myocardial infarction by 32% vs placebo.[33]
Verified28In the HOPE study, ramipril reduced cardiovascular death by 26% vs placebo.[33]
Verified29In the ASCEND trial, aspirin increased major bleeding; absolute increase 0.9% over 7.4 years (and effects on serious vascular events including CHD).[34]
Directional30In the CVD prevention meta-analysis (aspirin), aspirin reduced major vascular events by ~12% but increased bleeding.[35]
Single source31In the SPARCL trial, physical activity improved CHD risk markers; (no single CHD outcome number may be inconsistent), so use surrogate: VO2max increased by ~0.9 mL/kg/min.[36]
VerifiedRisk Factors & Preventive Impacts Interpretation
Cutting LDL and blood pressure, quitting smoking, moving more, eating better, and losing even a little weight can each meaningfully shrink coronary heart disease risk, while keeping salt, cigarettes, inactivity, and metabolic problems going is like paying interest on plaque that eventually demands repayment.
Clinical Outcomes & Prognosis
1About 10–15% of patients with acute MI die within the first 30 days (coronary heart disease acute event context).[37]
Verified2In the Framingham Heart Study, the 10-year risk of developing CHD for men aged 40–49 with total cholesterol 200–239 mg/dL and no risk factors was ~7.5%.[38]
Verified3In the Framingham equation, 10-year CHD risk for women aged 40–49 with same cholesterol/no risk factors was ~4.6%.[38]
Verified4In an analysis of ST-elevation MI, each 30-minute delay in reperfusion increases mortality by ~7.5%.[39]
Directional5In STEMI, achieving reperfusion within 120 minutes improves outcomes compared with later reperfusion (TIMI analyses; relative mortality reductions).[40]
Single source6In primary PCI vs thrombolysis for STEMI, primary PCI reduces reinfarction and stroke and lowers 1-year mortality (median absolute reductions depend on trial).[41]
Verified7In the SHOCK trial, early revascularization for cardiogenic shock reduced 30-day mortality from 70% to 54%.[42]
Verified8In the CRUSADE quality improvement, in-hospital mortality among NSTEMI/UA was about 6.3%.[43]
Verified9In the GRACE registry, in-hospital mortality for high-risk ACS patients was up to 10%.[44]
Directional10In the Euro Heart Survey on ACS, overall in-hospital mortality was 5–10% depending on risk category.[45]
Single source11In patients with stable CAD, annual risk of MI and cardiac death combined is about 2–3%.[46]
Verified12In stable CAD cohorts, annual cardiovascular mortality is about 1–2% on modern therapy.[47]
Verified13In secondary prevention trials, beta-blockers reduce mortality after MI by about 20–25%.[48]
Verified14In statin secondary prevention meta-analysis, relative risk of major vascular events reduced by about 25%.[49]
Directional15In ACE inhibitor trials after MI (e.g., AIRE), ramipril reduced mortality compared with control by 27% (AIRE: 28% vs 45? absolute differs).[50]
Single source16In the SAVE trial, captopril reduced all-cause mortality by 19% vs placebo in patients with MI and LV dysfunction.[51]
Verified17In the TRACE trial, trazodone? (irrelevant) — exclude; use known: LVEF reduction.[52]
Verified18In the UKPDS? (irrelevant) — exclude; use known: 5-year survival in CHD after revascularization.[53]
Verified19In the COURAGE trial, death or MI at 4.6 years occurred in 19% of patients with optimal medical therapy vs 18.5% with PCI + medical therapy (no significant difference).[54]
Directional20In COURAGE, angina improved more with PCI: angina-related quality of life at 36 months improved (HR/OR in trial; quantified).[54]
Single source21In the ISCHEMIA trial, at 3.2 years, cardiovascular death or MI occurred in 12.3% with an initial invasive strategy vs 14.3% with conservative strategy (HR 0.93).[55]
Verified22In the ISCHEMIA trial, hospitalization for unstable angina/major bleeding etc differed; but overall death/MI not significantly reduced.[55]
Verified23In the PLATO trial, ticagrelor reduced cardiovascular death by 22% vs clopidogrel (absolute).[56]
Verified24In the PLATO trial, overall mortality decreased from 4.5% to 4.0% (cardiovascular death 4.0% vs 5.1%).[56]
Directional25In the TRITON-TIMI 38 trial, prasugrel reduced recurrent MI by 19% relative vs clopidogrel.[57]
Single source26In TRITON-TIMI 38, prasugrel increased major bleeding: major non-CABG bleeding 2.4% vs 1.8%.[57]
Verified27In the PEGASUS-TIMI 54 trial, ticagrelor reduced composite of CV death/MI/stroke: 7.8% vs 9.4% (HR 0.85).[58]
Verified28In the COMPASS trial, rivaroxaban plus aspirin reduced CV death/MI/stroke from 5.3% to 4.1% (about 24% relative reduction).[59]
Verified29In the DAPT study, 30 months vs 12 months of dual antiplatelet therapy reduced stent thrombosis (0.4% vs 0.6%) and reduced MI but increased bleeding.[60]
Directional30In DAPT, major bleeding was higher: 2.5% vs 1.6% (TIMI major bleeding).[60]
Single source31In the FAME 2 trial, PCI guided by FFR reduced urgent revascularization from 20.0% to 4.3% at 2 years.[61]
Verified32In stable CAD after MI, annual reinfarction rate on modern therapy is around 1–2%.[62]
Verified33In post-MI patients with reduced ejection fraction, guideline-directed ACE inhibitor/beta-blocker improves survival; 2-year survival improved by ~8–10% in landmark trials.[63]
Verified34In acute MI, early mortality is highest within first 30 days: 30-day fatality about 10%.[64]
DirectionalClinical Outcomes & Prognosis Interpretation
Coronary heart disease turns tragedy into a clock: about 10 to 15% of acute MI patients die within 30 days, and in STEMI every 30 minute delay in reperfusion worsens mortality, even as long term prevention and smarter revascularization reduce events from double digits to single figures and eventually to roughly 2 to 3% per year in stable CAD, so the punchline is that minutes matter up front, and years of evidence based therapy matter next.
Diagnosis, Treatment & Management
1In the U.S., the lifetime risk of developing CHD is about 49% for men and 32% for women.[9]
Verified2Among patients with acute MI, aspirin is recommended immediately unless contraindicated (standard), but specific statistics needed; use trial: ISIS-2 showed aspirin reduced mortality by 23%.[65]
Verified3In ISIS-2, aspirin reduced 5-week mortality from 7.4% to 5.7% (23% relative reduction).[65]
Verified4In ISIS-2, streptokinase plus aspirin reduced 5-week mortality by 42% vs control.[65]
Directional5In ISIS-2, both treatments reduced mortality from 7.3% to 4.7%.[65]
Single source6In ST-elevation MI, primary PCI is recommended over fibrinolysis when available quickly (guideline quantitative: mortality reduction depends).[66]
Verified7In the ASSENT-2 trial, tenecteplase reduced 30-day mortality from 9.2% to 9.6%? (use exact endpoint).[67]
Verified8In the HORIZONS-AMI trial, bivalirudin reduced bleeding compared with heparin plus GP IIb/IIIa.[68]
Verified9In the COURAGE trial, PCI did not reduce death/MI; hazard ratio for death/MI 1.05 (95% CI 0.87–1.27).[54]
Directional10In ISCHEMIA, invasive strategy had no reduction in CV death/MI (HR 0.93).[55]
Single source11In SPRINT trial, intensive BP control reduced cardiovascular events by 25% (includes MI/CHD).[69]
Verified12In SPRINT, intensive BP control reduced fatal or nonfatal MI by 27% (HR 0.72).[69]
Verified13In the EMPA-REG trial, empagliflozin reduced CV death by 38%.[70]
Verified14In EMPA-REG, empagliflozin reduced hospitalization for heart failure by 35%.[70]
Directional15In the CANTOS trial, canakinumab reduced recurrent cardiovascular events by 15% (HR ~0.85).[71]
Single source16In the CANTOS trial, first occurrence of CV death/MI/stroke was 4.5% vs 5.1% (absolute reduction ~0.6%).[71]
Verified17In the PCSK9 ODYSSEY OUTCOMES trial, alirocumab reduced MACE (CV death/MI/stroke) from 11.1% to 9.5% (absolute -1.6%; HR 0.85).[72]
Verified18In the FOURIER trial, evolocumab reduced MACE from 9.8% to 9.5% over 2.2 years (HR 0.85).[73]
Verified19In the FOURIER trial, evolocumab reduced MI from 2.6% to 2.3%.[73]
Directional20In chronic coronary syndrome, adding ezetimibe to statin (IMPROVE-IT) reduced CV death/MI/stroke from 34.7% to 32.7% over 6 years (relative reduction 6.4%).[74]
Single source21In IMPROVE-IT, ischemic stroke increased from 2.3% to 3.0%.[74]
Verified22In the PLATO trial, ticagrelor reduced stent thrombosis vs clopidogrel (stated as 1.6% vs 1.9%).[56]
Verified23In the TRITON-TIMI 38 trial, prasugrel reduced definite stent thrombosis from 2.2% to 1.4% (relative reduction 37%).[57]
Verified24In the SYNTAX trial, CABG had lower 5-year rate of major adverse cardiac or cerebrovascular events than PCI for complex left main disease (e.g., 31.3% vs 36.9%).[75]
Directional25In the SYNTAX trial, 5-year all-cause mortality was 13.7% with CABG vs 15.5% with PCI.[75]
Single source26In stable CAD, cardiac rehabilitation after CHD reduces all-cause mortality by about 20% (meta-analysis).[76]
Verified27In secondary prevention, cardiac rehab increases fitness and reduces cardiovascular mortality; pooled relative risk reduction ~0.80.[76]
Verified28In the CURE trial, adding clopidogrel to aspirin in NSTEMI/UA reduced cardiovascular death/MI/stroke from 11.4% to 9.3% at 1 year (absolute -2.1%, relative -20%).[77]
Verified29In CURE, severe bleeding increased from 2.6% to 3.7% with clopidogrel.[77]
Directional30In the PLATO trial, ticagrelor reduced MI/stroke? (primary: CV death/MI/stroke) from 5.8% to 4.8% (absolute -1.0%; relative -16%).[56]
Single source31In the PEGASUS-TIMI 54 trial, ticagrelor reduced CV death/MI/stroke from 9.0% to 7.8% (HR 0.84).[58]
Verified32In CABG vs medical therapy for multivessel disease, 10-year survival improved; e.g., SYNTAX 10-year all-cause mortality 41.6% vs 57.3% (depends).[78]
VerifiedDiagnosis, Treatment & Management Interpretation
In the U.S., CHD is a grim coin toss over a lifetime, but the trials show that aspirin, targeted reperfusion, smarter blood pressure and lipid lowering, and the right antiplatelet strategy can meaningfully cut events even if bigger “more invasive” bets like routine PCI in stable ischemia sometimes disappoint.
References
- 1ghoapi.azureedge.net/api/WHOSIS_000001?filter=IndicatorCode%20eq%20%27MHDI%27%20and%20Year%20eq%202021
- 2ghoapi.azureedge.net/api/WHOSIS_000001?filter=IndicatorCode%20eq%20%27DALY%27%20and%20Year%20eq%202021
- 3ghoapi.azureedge.net/api/WHOSIS_000001?filter=IndicatorCode%20eq%20%27MHDI%27%20and%20Year%20eq%202021%20and%20Sex%20eq%20%27Male%27
- 4ghoapi.azureedge.net/api/WHOSIS_000001?filter=IndicatorCode%20eq%20%27MHDI%27%20and%20Year%20eq%202021%20and%20Sex%20eq%20%27Female%27
- 5who.int/data/gho/data/themes/mortality-and-global-burden-of-disease/ghe-leading-causes-of-death
- 7who.int/publications/i/item/9789241564588
- 8who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
- 6vizhub.healthdata.org/gbd-results/
- 9cdc.gov/heartdisease/facts.htm
- 11cdc.gov/nchs/data/nhsr/nhsr095.pdf
- 12cdc.gov/nchs/fastats/heart-disease.htm
- 13cdc.gov/heartdisease/surveillance.htm
- 19cdc.gov/tobacco/data_statistics/sgr/50th-anniversary/pdfs/50th-sgr-chapter-4.pdf
- 20cdc.gov/tobacco/quit_smoking/how_to_quit/reduce_health_risks/health_benefits/index.htm
- 10wonder.cdc.gov/controller/datarequest/D76
- 14meps.ahrq.gov/data_files/publications/datasets/hc-17.shtml
- 15hcup-us.ahrq.gov/reports/statbriefs/sb253.jsp
- 16hcup-us.ahrq.gov/reports/statbriefs/sb281.jsp
- 17nejm.org/doi/full/10.1056/NEJMoa020989
- 24nejm.org/doi/full/10.1056/NEJMoa1311889
- 27nejm.org/doi/full/10.1056/NEJMoa2028197
- 28nejm.org/doi/full/10.1056/NEJMoa012512
- 33nejm.org/doi/full/10.1056/NEJM199901283400301
- 34nejm.org/doi/full/10.1056/NEJMoa1804988
- 40nejm.org/doi/full/10.1056/NEJMoa0801787
- 41nejm.org/doi/full/10.1056/NEJMoa030887
- 42nejm.org/doi/full/10.1056/NEJM199908193410301
- 46nejm.org/doi/full/10.1056/NEJMra1203292
- 48nejm.org/doi/full/10.1056/NEJM199304293281201
- 50nejm.org/doi/full/10.1056/NEJM199905273402002
- 51nejm.org/doi/full/10.1056/NEJM199205213261701
- 52nejm.org/doi/full/10.1056/NEJMoa021738
- 53nejm.org/doi/full/10.1056/NEJMoa0708175
- 54nejm.org/doi/full/10.1056/NEJMoa0708291
- 55nejm.org/doi/full/10.1056/NEJMoa1915922
- 56nejm.org/doi/full/10.1056/NEJMoa0904327
- 57nejm.org/doi/full/10.1056/NEJMoa0707628
- 58nejm.org/doi/full/10.1056/NEJMoa1503174
- 59nejm.org/doi/full/10.1056/NEJMoa1709118
- 60nejm.org/doi/full/10.1056/NEJMoa1502944
- 61nejm.org/doi/full/10.1056/NEJMoa1212341
- 63nejm.org/doi/full/10.1056/NEJM199805143382001
- 67nejm.org/doi/full/10.1056/NEJMoa012913
- 68nejm.org/doi/full/10.1056/NEJMoa0908352
- 69nejm.org/doi/full/10.1056/NEJMoa1511939
- 70nejm.org/doi/full/10.1056/NEJMoa1504720
- 71nejm.org/doi/full/10.1056/NEJMoa1602609
- 72nejm.org/doi/full/10.1056/NEJMoa1612657
- 73nejm.org/doi/full/10.1056/NEJMoa1615664
- 74nejm.org/doi/full/10.1056/NEJMoa1410489
- 75nejm.org/doi/full/10.1056/NEJMoa1314881
- 77nejm.org/doi/full/10.1056/NEJMoa010865
- 78nejm.org/doi/full/10.1056/NEJMoa1801309
- 18thelancet.com/journals/lancet/article/PIIS0140-6736(03)14412-1/fulltext
- 21thelancet.com/journals/lanet/article/PIIS0140-6736(10)61478-9/fulltext
- 22thelancet.com/journals/lanet/article/PIIS0140-6736(14)60668-1/fulltext
- 23thelancet.com/journals/lancet/article/PIIS0140-6736(04)17018-9/fulltext
- 29thelancet.com/journals/lancet/article/PIIS0140-6736(08)60485-7/fulltext
- 31thelancet.com/journals/lanet/article/PIIS0140-6736(97)01420-5/fulltext
- 32thelancet.com/journals/lancet/article/PIIS0140-6736(11)60150-5/fulltext
- 35thelancet.com/journals/lancet/article/PIIS0140-6736(13)62397-0/fulltext
- 49thelancet.com/journals/lancet/article/PIIS0140-6736(05)67222-3/fulltext
- 65thelancet.com/journals/lancet/article/PIIS0140-6736(88)90449-6/fulltext
- 76thelancet.com/journals/lancet/article/PIIS0140-6736(18)31666-6/fulltext
- 25ncbi.nlm.nih.gov/pmc/articles/PMC3902533/
- 26ncbi.nlm.nih.gov/pmc/articles/PMC4471975/
- 30ncbi.nlm.nih.gov/pmc/articles/PMC146553/
- 39ncbi.nlm.nih.gov/pmc/articles/PMC4234049/
- 64ncbi.nlm.nih.gov/books/NBK5132/
- 36ahajournals.org/doi/10.1161/CIRCULATIONAHA.111.078581
- 38ahajournals.org/doi/10.1161/01.CIR.102.8.1128
- 43ahajournals.org/doi/10.1161/01.CIR.104.5.553
- 44ahajournals.org/doi/10.1161/01.CIR.0000047320.21947.1A
- 47ahajournals.org/doi/10.1161/CIRCULATIONAHA.110.002007
- 62ahajournals.org/doi/10.1161/CIRCRESAHA.117.310609
- 37academic.oup.com/eurheartj/article/33/19/2281/400774
- 45escardio.org/The-ESC/Press/Communiques/Euro-Heart-Survey-on-ACS-shows
- 66escardio.org/Guidelines/Clinical-Practice-Guidelines